



## Edward J. Yun Member

Healthcare Law

973.364.5229 · 973.618.5589 Fax  
eyun@bracheichler.com

**Edward helps clients resolve the broad spectrum of legal and business challenges that confront the healthcare industry.** He has broad, yet in-depth, experience representing individual professionals, multispecialty practices, ambulatory surgery centers, health technology companies, clinical laboratories, substance use disorder treatment facilities, home health agencies, hospitals, clinically integrated networks, clinical research foundations, and other health-related businesses. He often counsels healthcare clients in addressing complex issues that arise in healthcare transactions, facility license transfers, payor audits and recoupments, and day-to-day business affairs.

Edward's prior experience includes defending healthcare providers in Medicare, Medicaid, and insurance audits, licensing and administrative proceedings, commercial litigation, and appeals. He also defended healthcare providers against claims of medical malpractice, negligence, and products liability.

### INDUSTRIES

- Healthcare

### EDUCATION

- New York Law School, J.D.
- University of California at Berkeley, B.A.

### BAR AND COURT ADMISSIONS

- New Jersey
- New York
- U.S. District Court, Eastern District of New York
- U.S. District Court, Southern District of New York

## REPRESENTATIVE MATTERS

Each lawsuit handled by Edward depends on its unique facts and particular legal circumstances. The following are a list of results obtained by Edward on behalf of his clients:

- Provided legal analysis and business guidance in complying with the corporate practice of medicine doctrine and the prohibition against fee-splitting, self-referrals, kickbacks, false claims, and healthcare fraud.
- Structured and negotiated agreements for healthcare business transactions, mergers and acquisitions, and provider integrations.
- Represented private equity companies, parent companies, and their affiliated healthcare providers in obtaining government approvals for facility licenses, license transfers, and relocations, as well as Medicare enrollment and certification.
- Assisted clients in complying with participation and reimbursement requirements under Medicare, Medicaid, and commercial health plans, and in defending their audit and recoupment demands.
- Structured agreements for performance/value-based payment program arrangements with health plans and their provider networks.
- Advised healthcare providers and negotiated their participation agreements with commercial health plans.

\*Results may vary depending on your particular facts and legal circumstances.

## PROFESSIONAL ACTIVITIES

- American Health Lawyers Association
- National Association of Asian American Professionals

## AWARDS



The Best Lawyers®  
in America list\*

2025

\*No aspect of this advertisement has been approved by the Supreme Court of New Jersey.

[Click here for the Awards and Honors Methodology.](#)

---

### Insights

[Newsletters](#) - February 3, 2025

[Healthcare Law Update](#) - February 2025

---

[Articles](#) - November 27, 2024

---

**Teva Pharmaceuticals Pays \$450 Million to Settle Anti-Kickback and False Claims Act Allegations**

[Articles](#) - October 31, 2024

---

**Enhancing Oversight of Remote Patient Monitoring in Medicare**

[Articles](#) - October 31, 2024

---

**OIG Sheds Light on Medicare Advantage Gainsharing Arrangements**

[Articles](#) - October 1, 2024

---

**Shore Memorial Health System Settles False Claims Act Allegations Over Improper Receipt of PPP Loan**

[Newsletters](#) - October 1, 2024

---

**Healthcare Law Update - September 2024**

[Articles](#) - September 30, 2024

---

**Not-For-Profit's Patient Assistance Program Receives Favorable Advisory Opinion**

[Articles](#) - September 30, 2024

---

**Governor Murphy Forgives \$100 Million in Medical Debt**

[Articles](#) - August 30, 2024

---

**Guidelines for Identifying, Reporting, and Returning Medicare Overpayments**

[Articles](#) - August 30, 2024

---

**OIG Issues Two Advisory Opinions Regarding the Provision of Patient Travel and Fertility Subsidies in Connection to Gene Therapy**

---